EMA approves Dupixent as first biologic for COPD with elevated eosinophils
The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease ... Read More
AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ... Read More